DiaSorin (FTSE Italia Mid Cap: DIA) announced today that they have received clearance from the US Food and Drug Administration to market the Simplexa C. difficile Direct Assay for the detection of Clostridium difficile (C. difficile).
Data Innovations (DI) today announces the launch of version 8.15 of Instrument Manager (IM), the latest version of the leading middleware product. This version provides technology enhancements to our Hot Backup solution and introduces an additional option called High Availability.
Olympus, a global technology leader in imaging solutions, will have its experts available for product demonstrations at the 69th AACC Annual Scientific Meeting & Clinical Lab Expo July 30 - August 3 in San Diego. The Olympus booth (#3433) will be exhibiting the BX53, BX46, and CX23 microscopes, as well as the DP74.
For more information or to schedule an interview and hands-on demonstration with a product expert, please email Kristin Schaeffer at [email protected].
When Clippard invented miniature regulators in 1962, the MAR Series became very popular as a simple, robust, and cost-effective regulator in a small package with exceptionally long life. As regulator applications continue to increase, Clippard is meeting the demand with the newest addition to the reputable regulator line. The new DR-2 Series provides greater accuracy and repeatability (±0.15 psi) while maintaining the same flow and performance characteristics as the MAR regulators in a small, sleek package.
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global provider of life science research and clinical diagnostic products, today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) for its IH-1000 blood typing instrument along with approvals for a wide range of associated gel cards and reagents for the U.S. blood typing market. The system offers full automation and walk-away reliability, allowing laboratories to more efficiently manage their blood testing workload.
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global provider of life science research and clinical diagnostic products, today announced its continued expansion into the molecular diagnostics testing market with the launch of Amplichek™ I quality control, which was recently issued a 510(k) clearance from the U.S. Food and Drug Administration (FDA).
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global provider of life science research and clinical diagnostic products, today announced it has received U.S. Food and Drug Administration (FDA) clearance for its BioPlex® 2200 Syphilis Total & RPR assay, a novel one-step universal testing method to aid in the diagnosis of syphilis infection.
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global provider of life science research and clinical diagnostic products, announced today that it has entered into a definitive agreement to purchase RainDance Technologies, Inc. The terms of the acquisition were not disclosed. Bio-Rad expects the transaction to close during the first quarter of 2017. The company will discuss the acquisition further during Bio-Rad’s upcoming fourth-quarter and full-year 2016 financial results conference call.
Illumina, Inc. (NASDAQ: ILMN) and Bio Rad Laboratories, Inc. (NYSE: BIO)(NYSE: BIOb) today announced the launch of the Illumina® Bio-Rad® Single-Cell Sequencing Solution at the J.P. Morgan Healthcare Conference, San Francisco. The comprehensive solution is the first next-generation sequencing (NGS) workflow for single-cell analysis, providing researchers the ability to investigate the coordinated contribution of individual cells in tissue function, disease progression, and therapeutic response.
Artel, the technology leader in liquid handling quality assurance, today announced the release of its new PCS® Software. Fully compatible with Artel’s current PCS instruments, the software will also be integrated with the latest generation of the Pipette Calibration System (PCS), to be available late 2016.
At the AACC Expo 2017, the Australian designer and manufacturer of lab automation systems, Aim Lab Automation Technologies Pty Ltd, will unveil its latest PathFinder automation platform – the PathFinder 350D - for automating the de-capping and sorting of incoming blood collection tubes directly into various analyzer racks ready for analysis.
Based on our proven sample processing technology, Addcare has developed an automated DNA Extraction Workstation, increasing safety and throughput of complex and time consuming preparation of DNA amplification procedures. The system incorporates a high precision 4-channel pipetting system with disposable tips for transfer and mixing of samples and reagents capable of piercing sealed microplates, microplate shaker/incubators to accommodate standard and deep well microplates and cooling modules for PCR tubes and reagent containers. The plate handler transfers plates between processing positions on the platform and a barcode scanner supports sample identification.
Addcare applies state of the state of the art technology, know-how and processes to provide high quality systems which perfectly integrate into your laboratory environment.
Addcares liquid handling and assay processing platforms are designed to efficiently automate routine sample preparation, other liquid handling task and a variety of assays in your laboratory. They are an indispensable tool to increase efficiency, throughput and safety in your lab. Lab technicians will be released from time consuming routine and freed capacity will be available for other, valuable tasks.
Addcare's range of ELISA workstations are designed to increase productivity and quality of immunoassay processing in your lab. They combine all functions required to process microplate based immunoassays on an efficient and flexible platform. A variety of models for small, medium to high throughput sample volumes are designed to perfectly match the needs of your individual lab. Alternative configurations for chemiluminescence and fluorescence immunoassays extend the portfolio. Assay processing is defined and controlled by ADCstation, Addcare's powerful PC-software.
Addcare fully automated blood grouping system using microcolumn gel card method, simple operation, high sensitivity, can detect low levels of antigen antibody, the results clearly feasible, easy to save, and meet a variety of data management requirements, suitable for large and medium-sized hospitals, blood stations, CDC and other units of the ABO blood type positive and negative type automatic detection, Rh (d) and irregular antibody screening, cross matching, etc. Product details: blood bank system 1 Using Mirocolumn gel card ,results fast and accurate.2. with emergency function, priority processing emergency test .3. wide catch card, catch card is more stable and firm.4. Using image processing system of high resolution, and preserve the original image, easy to trace results at any time.
ASCO's Rapid Engineered Solutions program delivers customized miniature valve assemblies in a matter of days to analytical and medical instrument original equipment manufacturing (OEM) customers.
Bio-Rad Laboratories, Inc. a global provider of life science research and clinical diagnostic products, today announced the addition of four new analytes to the company’s Liquichek Tumor Marker Control.
Sysmex America introduced the XN-V Series Software for Automated Hematology Analyzers* in the United States and Canada. The XN-V series is the next generation of hematology analyzers geared toward the acceleration of research in the scientific community.
ERBA Diagnostics, Inc. (OTC PINK:ERBA) (the “Company”), a fully integrated in vitro diagnostics company, announced today that, effective as of August 1, 2017, David Barka will become the Interim Chief Executive Officer (“CEO”) of the Company and Nikhil Vazirani will join the Board of Directors (the “Board”).
For more than 65 years, Conductive Technologies Inc., has enabled innovation for Medical Device Manufacturers, Startups, Academia and Foundations. From electrochemical biosensors to printed circuitry, and RFID tags to PTC Heaters, our staff of innovative scientists and engineers assist our customers with depth of knowledge, thorough development and timely delivery.
Clippard's SV series of direct actuating valves offer an extremely fast response time for accurate dosing of minute volumes with the same long life you expect from the original Clippard EV line of valves, now in a 7 mm cartridge package.
Clippard NPV Series Miniature Pinch Valves are solenoid-operated devices designed to open and close tubes for controlling flow of liquids and gases. Other valve types have internal passages that may cause small amounts of fluid to remain in the valve. Pinch valves have no areas or dead volume where fluid can become trapped. Only the inside of the tubing contacts the fluid. Energizing the solenoid retracts or attracts the plunger, which opens or closes the tube. De-energizing the solenoid will allow the plunger to return to its original state.
The Clippard NPV Series Miniature Pinch Valve is a solenoid-operated device that is designed to open and close tubes for controlling flow of liquids and gases. Other valve types have internal passages that may cause small amounts of fluid to remain in the valve. Pinch valves have no areas or dead volume where fluid can become trapped. Only the inside of the tubing contacts the fluid. Energizing the solenoid retracts or attracts the plunger, which opens or closes the tube. De-energizing the solenoid will allow the plunger to return to its original state.
The Clippard NIV Series Media Isolation Valve is a solenoid-operated device that uses a flexible diaphragm to isolate the actuation mechanism from the fluid path. Media isolation valves are commonly used for a wide variety of applications, including those that require precise, repeatable dispensing of media for analytical instrumentation.
XimedicaDx, formerly known as Accel Biotech, is proud to unveil their comprehensive rebranding, which is officially being revealed at the 69th AACC Clinical Lab Expo in San Diego. The change comes in alignment with their acquisition by Ximedica, a leading full service medical technologies development firm, in July of 2016. XimedicaDx maintains Accel Biotech’s comprehensive experience and expertise in in-vitro diagnostics and life science product development as Ximedica’s Diagnostics Center of Excellence.
Press Release by Microscan on demonstration of the latest advancements of barcode and machine vision technologies at the AACC Annual Scientific Meeting and Clinical Lab Expo on August 1-3 in San Diego, CA.
We would like to introduce you our independently developed instruments, including automatic biochemical analyzer and automatic 6-channel POCT, with supporting reagents in various areas for distribution and OEM
Tosoh Bioscience is proud to showcase Biotin Interference Free immunoassay testing at AACC 2017. Tosoh’s full AIA-PACK® test menu offers a complete line of immunoassay tests that are all free from biotin interference.
JADAK, a business unit of Novanta Corporation, is exhibiting at the 69th annual AACC Clinical Lab Expo from August 1st – 3rd, 2017 in San Diego, CA, Booth #2818. JADAK’s exhibit will feature its new Clarity™ 2.0 Machine Vision & Image Analysis Software, demonstrated within a desktop analyzer, as well as its expanded line of Ultra High Frequency (UHF) RAIN RFID products and Near Field Communications (NFC) High Frequency (HF) RFID product line
Abraxis, Inc., announces expansion of its AbraMag magnetic beads line for molecular biology, biochemistry and sample prep applications, with the addition of mRNA purification beads and kit.
IVD Industry Connectivity Consortium™ (IICC) to present the LIVD specification and IICC/IHE LAW Profile at the 69th AACC Annual Scientific Meeting & Clinical Lab Expo in San Diego, CA
Sysmex America announced its latest innovation: a way to make quality assurance easier and more risk free than manual quality control processes. “Sysmex is well known for the innovation that it delivers to the laboratory. BeyondCare Quality Monitor elevates quality assurance processes to a new level with automated, continuous monitoring and guidance in an easy-to-use framework,” said Ralph Taylor, chief executive officer.
Clinical laboratories could significantly improve healthcare for the transgender community by using both sex and gender identity to make decisions about clinical testing, and by determining normal lab values for healthy transgender patients. A review published today in AACC’s Clinical Chemistry journal emphasizes these as critical steps on the road to eliminating the many hurdles that transgender individuals face when seeking quality healthcare.
A review published today in AACC’s Clinical Chemistry journal has identified 10 genes that show promise in predicting how patients will respond to opioid pain medications. Using these genetic markers, healthcare providers could potentially tailor opioid therapy better to curb the skyrocketing rate of deaths from these drugs.
AACC, a global scientific and medical professional organization dedicated to better health through laboratory medicine, is pleased to announce that the impact factor of its journal, Clinical Chemistry, has risen to 8.008 in the 2016 Thomson Reuters Journal Citation Reports. This impact factor places Clinical Chemistry in the top 2.6% of 12,062 ranked academic journals and speaks to the significant influence of the science it publishes on laboratory medicine and patient care.
A groundbreaking study published today in AACC’s Journal of Applied Laboratory Medicine shows that a new test could improve diagnosis and treatment of heart disease by measuring how effectively a patient’s high-density lipoprotein cholesterol (HDL-C) cleans up arterial cholesterol.
In response to ongoing Medicare reimbursement changes that aim to enhance patient care while reducing healthcare costs, AACC released a position statement today emphasizing that clinical laboratory tests must be used effectively for this new payment system to achieve its objectives. The statement advocates for increased collaboration between physicians and laboratory medicine professionals, who have the expertise to ensure that the right test is ordered for each patient and that results are interpreted correctly.
Breaking research published today in AACC’s Journal of Applied Laboratory Medicine reveals that a number of diagnostic tests are less accurate when performed in pediatric patients with impaired kidney function. These findings show that healthcare providers should assess patient kidney function when interpreting clinical test results for certain conditions to ensure that patients receive the correct diagnoses and treatments.
A study published today in AACC’s Journal of Applied Laboratory Medicine describes the creation of a first-of-its-kind patient sample bank that could improve consistency among blood tests used to diagnose heart attacks and advance care for cardiac patients.
In response to rising concern that many published scientific results may be false, the Reproducibility Project: Cancer Biology set out to replicate findings from the 50 most cited cancer studies from 2010–2012. A perspective in AACC’s Clinical Chemistry journal discusses the project’s preliminary results and suggests changes the research community can make to prevent reproducibility issues from inhibiting cancer care.
AACC, a global scientific and medical professional organization dedicated to better health through laboratory medicine, is pleased to announce the recipients of the 2017 AACC and AACC Academy Awards. Through this annual awards program, AACC and its academy strive to support laboratory medicine professionals in all stages of their careers and to build public awareness that clinical laboratory testing plays a critical role in improving patient health.
Since 2012, research teams in the Qualcomm Tricorder Xprize competition have vied to create a mobile diagnostic device modeled after the fictional medical tricorder from Star Trek. For the first time, competition finalist Chung-Kang Peng, PhD, will present data on his team’s tricorder prototype in a special session at the 69th AACC Annual Scientific Meeting & Clinical Lab Expo in San Diego.
Though marijuana edibles are becoming increasingly common, scant information exists on how to test drivers for impairment following their consumption. For the first time, research published today in AACC’s Clinical Chemistry journal evaluates the performance of roadside saliva tests for tetrahydrocannabinol (THC) following consumption of edibles, showing that lower THC cutoff points are needed for these tests to effectively detect marijuana ingestion.
AACC, a global scientific and medical professional organization dedicated to better health through laboratory medicine, is pleased to announce the launch of AACC Learning Lab. Developed through a collaboration with NEJM Group—the publisher of the New England Journal of Medicine, and Area9 Learning—a global leader in adaptive learning technology—AACC Learning Lab is designed to help laboratory medicine experts expand their knowledge and enhance their ability to find answers to challenging patient health problems.
For the first time, researchers have developed tests that could improve treatment for heart failure patients by diagnosing the condition with greater accuracy, as well as by detecting the onset of congestive heart failure earlier. The findings were published in the Cardiovascular Disease issue of Clinical Chemistry, the journal of AACC.
Research published today in AACC’s Clinical Chemistry journal shows that a test can identify patients with a history of cardiovascular disease who are at high risk of another heart attack or death and would benefit from treatment with the drug vorapaxar. This study and two others on tests that predict risk of adverse cardiovascular events are featured in the Cardiovascular Disease issue of Clinical Chemistry.
Laboratory medicine experts are using a growing understanding of the molecular signatures of heart disease to develop more precise tests for the early diagnosis, monitoring, and targeted treatment of this condition. A special issue of Clinical Chemistry, the journal of AACC, titled “Cardiovascular Disease: Impact of Biomarkers, Proteomics, and Genomics,” highlights the groundbreaking medical tests that could advance patient care for this chronic disease and its consequences, which range from cardiac arrest to congestive heart failure.